Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies

被引:66
|
作者
Albrecht, Katinka [1 ]
Zink, Angela [1 ,2 ]
机构
[1] German Rheumatism Res Ctr, Epidemiol Unit, Charitepl 1, D-10117 Berlin, Germany
[2] Charite, Rheumatol & Clin Immunol, D-13353 Berlin, Germany
关键词
Rheumatoid arthritis; Prognostic factors; Treatment; Outcome; RAPID RADIOGRAPHIC PROGRESSION; MODIFYING ANTIRHEUMATIC DRUGS; DISEASE-ACTIVITY; TREATMENT RESPONSE; DOUBLE-BLIND; RISK MODEL; RECOMMENDATIONS; REMISSION; SOCIETY; UPDATE;
D O I
10.1186/s13075-017-1266-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prognostic factors are used for treatment decisions in rheumatoid arthritis ( RA). High disease activity, the early presence of erosions, and autoantibody positivity are the most frequently used poor prognostic factors but other features, such as functional disability, extraarticular disease, or multibiomarkers, are also assessed. Prognostic factors are incorporated in current treatment recommendations for the management of RA and are used as inclusion criteria in randomized controlled trials. They are defined heterogeneously and the relevance of a single or combined presence of poor prognostic factors remains unclear. This review summarizes the current definitions of poor prognostic factors and their use in clinical research. Perspectives on future research are also outlined.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] High Survivin Levels Predict Poor Clinical Response to Infliximab Treatment in Patients with Rheumatoid Arthritis
    Isgren, Anniella
    Forslind, Kristina
    Erlandsson, Malin
    Axelsson, Carl
    Andersson, Sofia
    Lund, Anneli
    Bokarewa, Maria
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2012, 41 (05) : 652 - 657
  • [22] Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis
    Liu Jia-Jia
    Li Ru
    Gan Yu-Zhou
    Zhang Rui-Jun
    Li Jing
    Cai Yue-Ming
    Zhao Jin-Xia
    Liao Hua
    Xu Jing
    Shi Lian-Jie
    Li Ji
    Li Sheng-Guang
    Sun Xiao-Lin
    He Jing
    Liu Xu
    Ye Hua
    Li Zhan-Guo
    中华医学杂志英文版, 2019, 132 (09) : 1009 - 1014
  • [23] Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients
    Thomas, Konstantinos
    Lazarini, Argiro
    Kaltsonoudis, Evripidis
    Drosos, Alexandros
    Papalopoulos, Ioannis
    Sidiropoulos, Prodromos
    Tsatsani, Panagiota
    Gazi, Sousana
    Pantazi, Lina
    Boki, Kyriaki A.
    Katsimbri, Pelagia
    Boumpas, Dimitrios
    Fragkiadaki, Kalliopi
    Tektonidou, Maria
    Sfikakis, Petros P.
    Karagianni, Konstantina
    Sakkas, Lazaros I.
    Grika, Eleftheria P.
    Vlachoyiannopoulos, Panagiotis G.
    Evangelatos, Gerasimos
    Iliopoulos, Alexios
    Dimitroulas, Theodoros
    Garyfallos, Alexandros
    Melissaropoulos, Konstantinos
    Georgiou, Panagiotis
    Areti, Maria
    Georganas, Constantinos
    Vounotrypidis, Periklis
    Kitas, George D.
    Vassilopoulos, Dimitrios
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020, 12
  • [24] Which patients with rheumatoid arthritis do not receive DMARD treatment? Analysis of data from the German Collaborative Arthritis Centers
    Thiele, K.
    Callhoff, J.
    Eidner, T.
    Hoese, G.
    Karberg, K.
    Wassenberg, S.
    Zink, A.
    Albrecht, K.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (02): : 153 - 159
  • [25] Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
    Moots, Robert J.
    Sebba, Anthony
    Rigby, William
    Ostor, Andrew
    Porter-Brown, Benjamin
    Donaldson, Francis
    Dimonaco, Sophie
    Rubbert-Roth, Andrea
    van Vollenhoven, Ronald
    Genovese, Mark C.
    RHEUMATOLOGY, 2017, 56 (04) : 541 - 549
  • [26] Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials
    Tanaka, Yoshiya
    Izutsu, Hiroyuki
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (09) : 1015 - 1025
  • [27] Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis
    Kojima, Toshihisa
    Yabe, Yuichiro
    Kaneko, Atsushi
    Hirano, Yuji
    Ishikawa, Hisato
    Hayashi, Masatoshi
    Miyake, Hiroyuki
    Takagi, Hideki
    Kato, Takefumi
    Terabe, Kenya
    Wanatabe, Tsuyoshi
    Tsuchiya, Hiroki
    Kida, Daihei
    Shioura, Tomone
    Funahashi, Koji
    Kato, Daizo
    Matsubara, Hiroyuki
    Takahashi, Nobunori
    Hattori, Yosuke
    Asai, Nobuyuki
    Ishiguro, Naoki
    MODERN RHEUMATOLOGY, 2013, 23 (05) : 977 - 985
  • [28] Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
    Westhovens, R.
    Robles, M.
    Ximenes, A. C.
    Nayiager, S.
    Wollenhaupt, J.
    Durez, P.
    Gomez-Reino, J.
    Grassi, W.
    Haraoui, B.
    Shergy, W.
    Park, S-H
    Genant, H.
    Peterfy, C.
    Becker, J-C
    Covucci, A.
    Helfrick, R.
    Bathon, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (12) : 1870 - 1877
  • [29] Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study
    Kojima, Toshihisa
    Yabe, Yuichiro
    Kaneko, Atsushi
    Takahashi, Nobunori
    Funahashi, Koji
    Kato, Daizo
    Hanabayashi, Masahiro
    Asai, Shuji
    Hirabara, Shinya
    Asai, Nobuyuki
    Hirano, Yuji
    Hayashi, Masatoshi
    Miyake, Hiroyuki
    Kojima, Masayo
    Ishiguro, Naoki
    RHEUMATOLOGY, 2015, 54 (01) : 113 - 120
  • [30] Variation and implications of treatment decisions in early rheumatoid arthritis: results from a nationwide cohort study
    Yates, Mark
    MacGregor, Alexander J.
    Ledingham, Jo
    Norton, Sam
    Bechman, Katie
    Dennison, Elaine M.
    Galloway, James B.
    RHEUMATOLOGY, 2020, 59 (08) : 2035 - 2042